James Jen Kin
Psychiatry · Long Beach, CANPI 1548238819
Payments from drug & device makers
Across 839 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Alkermes, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Teva Pharmaceuticals USA, Inc.$2K
- Johnson & Johnson$1K
- Otsuka America Pharmaceutical, Inc.$1K
- plus $5K from 23 others
What the payments were for
- Food & beverage$15,940100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 128 | $2,349 |
| Alkermes, Inc. | 98 | $2,085 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 113 | $1,930 |
| Teva Pharmaceuticals USA, Inc. | 103 | $1,737 |
| Johnson & Johnson | 73 | $1,287 |
| Otsuka America Pharmaceutical, Inc. | 61 | $1,269 |
| Vanda Pharmaceuticals Inc. | 56 | $1,120 |
| Neurocrine Biosciences, Inc. | 43 | $1,071 |
| Lundbeck LLC | 42 | $893 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $385 |
| Axsome Therapeutics, Inc. | 8 | $218 |
| Almatica Pharma LLC | 13 | $196 |
| Corium, LLC | 12 | $170 |
| Tris Pharma Inc | 13 | $169 |
| Eisai Inc. | 8 | $152 |
| Ironshore Pharmaceuticals Inc. | 7 | $148 |
| Supernus Pharmaceuticals, Inc. | 7 | $108 |
| Indivior Inc. | 5 | $102 |
| Adlon Therapeutics L.p. | 6 | $93 |
| Idorsia Pharmaceuticals US Inc | 5 | $87 |
| Bausch Health US, LLC | 4 | $86 |
| Sage Therapeutics, LLC | 3 | $73 |
| E.r. Squibb & Sons, L.L.C. | 2 | $51 |
| Neuronetics, Inc. | 2 | $47 |
| Noven Therapeutics, LLC | 2 | $41 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Livanova USA, Inc. | 1 | $22 |
| Merck | 1 | $21 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
How this compares
$15,945 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 12 | $61,604 |
| CaplytaLumateperone Tosylate | 24 | $48,086 |
| RexultiBrexpiprazole | 21 | $29,381 |
| Invega SustennaPaliperidone Palmitate | 13 | $14,528 |
| Lurasidone Hcl | 39 | $10,209 |
| Aripiprazole | 139 | $8,185 |
| Loreev XrLorazepam | 15 | $7,518 |
| BelsomraSuvorexant | 14 | $6,994 |
| Olanzapine OdtOlanzapine | 39 | $4,978 |
| Fluphenazine Hcl | 14 | $4,144 |
| Sertraline Hcl | 155 | $3,740 |
| Quetiapine Fumarate | 247 | $3,706 |
| Asenapine Maleate | 13 | $3,636 |
| Olanzapine | 84 | $3,487 |
| Divalproex Sodium | 59 | $2,839 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $1,737 | $61,60412 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,930 | $48,08624 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,269 | $29,38121 claims |
| Johnson & JohnsonInvega Sustenna | $1,287 | $14,52813 claims |
| Almatica Pharma LLCLoreev Xr, Sertraline Hcl | $196 | $11,258170 claims |
| MerckBelsomra | $21 | $6,99414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Long Beach
- Haig GoenjianLong Beach$6.3M
- Armen GoenjianLong Beach$5.3M
- Christopher ReistLong Beach$2.9M
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.